BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mielnik CA, Lam VM, Ross RA. CB1 allosteric modulators and their therapeutic potential in CNS disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2021;106:110163. [DOI: 10.1016/j.pnpbp.2020.110163] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Egyed A, Kiss DJ, Keserű GM. The Impact of the Secondary Binding Pocket on the Pharmacology of Class A GPCRs. Front Pharmacol 2022;13:847788. [PMID: 35355719 DOI: 10.3389/fphar.2022.847788] [Reference Citation Analysis]
2 Zanfirescu A, Nitulescu G, Mihai DP, Nitulescu GM. Identifying FAAH Inhibitors as New Therapeutic Options for the Treatment of Chronic Pain through Drug Repurposing. Pharmaceuticals (Basel) 2021;15:38. [PMID: 35056095 DOI: 10.3390/ph15010038] [Reference Citation Analysis]
3 Nguyen T, Gamage TF, Finlay DB, Decker AM, Langston TL, Barrus D, Glass M, Li JX, Kenakin TP, Zhang Y. Development of 3-(4-Chlorophenyl)-1-(phenethyl)urea Analogues as Allosteric Modulators of the Cannabinoid Type-1 Receptor: RTICBM-189 is Brain Penetrant and Attenuates Reinstatement of Cocaine-Seeking Behavior. J Med Chem 2021. [PMID: 34929081 DOI: 10.1021/acs.jmedchem.1c01432] [Reference Citation Analysis]
4 Raux PL, Drutel G, Revest JM, Vallée M. New perspectives on the role of the neurosteroid pregnenolone as an endogenous regulator of type-1 cannabinoid receptor (CB1R) activity and function. J Neuroendocrinol 2021;:e13034. [PMID: 34486765 DOI: 10.1111/jne.13034] [Reference Citation Analysis]
5 Morris G, Walder K, Kloiber S, Amminger P, Berk M, Bortolasci CC, Maes M, Puri BK, Carvalho AF. The endocannabinoidome in neuropsychiatry: Opportunities and potential risks. Pharmacol Res 2021;170:105729. [PMID: 34119623 DOI: 10.1016/j.phrs.2021.105729] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Coronado-Álvarez A, Romero-Cordero K, Macías-Triana L, Tatum-Kuri A, Vera-Barrón A, Budde H, Machado S, Yamamoto T, Imperatori C, Murillo-Rodríguez E. The synthetic CB1 cannabinoid receptor selective agonists: Putative medical uses and their legalization. Prog Neuropsychopharmacol Biol Psychiatry 2021;110:110301. [PMID: 33741446 DOI: 10.1016/j.pnpbp.2021.110301] [Reference Citation Analysis]